Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

NCT00403442 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DEVICE: Verteporfin Therapy/ Drug: Bevacizumab

Sponsor

Vitreous -Retina- Macula Consultants of New York

Collaborators

[object Object]